可扩展的高通量平台为单个细胞的基因表达提供了前所未有的深入视角
大多数科学研究依赖于对大块组织样本的分析。这些样本通常是由多种类型且各具有不同功能的细胞组成的。这些细胞的基因表达数据被平均化，使得人们难以确定细胞之间的差异，更不要说了解细胞差异的作用。单细胞测序解决了这些挑战，让人们更深入洞察细胞功能、疾病进展和治疗反应。例如，这些数据在神经组织的研究中应该非常重要，大家都知道神经组织含有数百种特化的细胞类型。
利用Bio-Rad一流的微滴分液技术和Illumina领先的NGS技术，这个新方案将优化单细胞的分离和添加条形码步骤，以适应下游的测序。数据分析是通过Illumina的云端基因组学计算环境BaseSpace开展的。与现有的方案相比，这个方案可扩展到分离数量远比现在大量得多的单细胞，只需数分钟，而且价格实惠。
“我们很高兴有机会与全球NGS技术的领导者Illumina合作，开发这一期待已久的单细胞基因组学平台，”Bio-Rad的执行副总裁、数字生物学中心总经理Annette Tumolo谈道。“通过此次合作，我们将为单细胞表达分析带来一个无缝并且可扩展的解决方案。”
“通过与
这两家公司预计将在2016年末或2017年初推出解决方案。
关于
关于
Illumina公司通过释放基因组的力量而改善人类健康。我们注重创新，这使我们成为DNA测序和芯片技术的全球领导者，并为科研、临床和应用市场的客户提供服务。我们的产品应用在生命科学、肿瘤学、生殖保健、农业及其他新兴市场上。如欲了解更多信息，请访问www.illumina.com.cn或关注 @illumina。
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, problems we may encounter with our supply chain and product quality issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111006404/en/
Source:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com
or
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
